{
    "clinical_study": {
        "@rank": "78967", 
        "arm_group": [
            {
                "arm_group_label": "Modified Citrus Pectin (MCP)", 
                "arm_group_type": "Active Comparator", 
                "description": "Dietary Supplement: Modified Citrus Pectin (MCP, PectaSol-C), 5 grams by mouth three times a day"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Matched placebo 5 grams by mouth three times a day"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will investigate if Modified Citrus Pectin (MCP) can help people with high blood\n      pressure.  MCP is a dietary supplement that is derived from plants, and therefore is not\n      subject to approval by the U.S. Food and Drug Administration (FDA).  However, MCP has been\n      deemed as 'generally regarded as safe' by the FDA.\n\n      This study will examine whether Modified Citrus Pectin (MCP) can help people with high blood\n      pressure.  The study will help understand how MCP may affect the risk for heart disease in\n      patients with high blood pressure."
        }, 
        "brief_title": "Galectin-3 Blockade in Patients With High Blood Pressure", 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "detailed_description": {
            "textblock": "Gal-3 appears to be a potential mediator of cardiac fibrosis, preceding the development of\n      clinical heart failure.  In this study, we seek to identify individuals at risk for the\n      development of HF based on clinical hypertension and elevated Gal-3 concentrations.\n      Participants will be randomized to receive a Gal-3 inhibitor (MCP) or placebo.  The primary\n      outcome will be the effect on collagen metabolism, and secondary outcomes include\n      echocardiographic measures of cardiac structure and function, and non-invasive measures of\n      vascular function."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 21-70 years\n\n          -  Physician diagnosed hypertension on stable therapy for 3 months\n\n          -  Elevated galectin-3 level (upper quartile based on Framingham Heart Study measures)\n\n          -  Able to understand the protocol and provide informed consent in English\n\n        Exclusion Criteria:\n\n          -  Uncontrolled hypertension, defined as SBP > 170mmHg, DBP > 100mmHg\n\n          -  Evidence of secondary hypertension\n\n          -  History of HF, coronary artery disease, stroke, atrial fibrillation\n\n          -  LVEF < 45% on echocardiography\n\n          -  Use of aldosterone antagonists\n\n          -  History of liver cirrhosis\n\n          -  History of pulmonary fibrosis\n\n          -  Kidney dysfunction, defined as estimated glomerular filtration rate < 60\n             ml/min/1.73m2\n\n          -  Anemia, defined as hematocrit < 38% in men and < 36% in women\n\n          -  Use of chelating agents\n\n          -  History of cancer or malignancy\n\n          -  Known pregnancy, those unwilling to avoid pregnancy during the course of the study,\n             or women currently breastfeeding\n\n          -  Hyperkalemia on screening labs, defined as K>5.0\n\n          -  Anticipated inability to complete or comply with study protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01960946", 
            "org_study_id": "H-32285", 
            "secondary_id": "1K23HL116780"
        }, 
        "intervention": {
            "arm_group_label": "Modified Citrus Pectin (MCP)", 
            "description": "5 grams by mouth three times a day", 
            "intervention_name": "Modified Citrus Pectin (MCP)", 
            "intervention_type": "Dietary Supplement", 
            "other_name": [
                "MCP", 
                "PectaSol-C"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Pectin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hypertension", 
            "Galectin 3", 
            "Fibrosis", 
            "Vascular Stiffness", 
            "Echocardiography"
        ], 
        "lastchanged_date": "November 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02118"
                }, 
                "name": "Boston University Medical Center"
            }, 
            "investigator": {
                "last_name": "Jennifer E Ho, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension", 
        "overall_contact": {
            "email": "jennifer.ho@bmc.org", 
            "last_name": "Jennifer E Ho, MD"
        }, 
        "overall_official": {
            "affiliation": "Boston University", 
            "last_name": "Jennifer E Ho, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Primary aim will be change in markers of collagen metabolism (PICP, PIIICP, ICTP, TIMP-1) in MCP versus placebo groups over 6 months of treatment.", 
            "measure": "Change in markers of collagen metabolism", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01960946"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Changes in galectin-3 level from baseline until 6 months will be compared between MCP and placebo groups", 
                "measure": "Change in galectin-3 level", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 6 months"
            }, 
            {
                "description": "Changes in cardiac structure and function will be examined using 2-D echocardiography and tissue Doppler imaging.  This will include changes in LV mass, dimensions, LA size, and LV diastolic function.", 
                "measure": "Changes in cardiac structure and function", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 6 months"
            }, 
            {
                "description": "We will examine changes in arterial stiffness (including augmentation index, carotid-femoral pulse-wave velocity) from baseline to 6 months in the MCP and placebo groups", 
                "measure": "Changes in arterial stiffness", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 6 months"
            }
        ], 
        "source": "Boston Medical Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Heart, Lung, and Blood Institute (NHLBI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Boston Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}